Tuberculosis is the world's leading infectious cause of death, killing more than one million people each year. When the antibiotic bedaquiline was introduced in 2012, it was the first new tuberculosis ...

Using nuclear magnetic resonance (NMR) spectroscopy, chemists have discovered how the structure of E. coli’s EmrE efflux pump—a transporter that can pump toxic molecules like antibiotics out of ...

Mycobacteria, notably Mycobacterium tuberculosis, employ active efflux systems to export antibiotics and reduce intracellular drug concentrations, thereby contributing to both intrinsic tolerance and ...

The medical profession is in the midst of losing an arms race. Bacterial antibiotic resistance doesn't just threaten our ability to treat infection but our ability to carry out any treatment where ...

Besides their normal role, pump overexpression confers drug resistance. Knowing the structure is a step to disabling the pumps with inhibitors BIRMINGHAM, Ala. – Tuberculosis is the world’s leading ...

Researchers headed by a team at King’s College London have developed a new way of designing antibiotics that could support the discovery of new treatments for drug-resistant infections. Designed to ...

Scientists at Fujifilm Corp. and Osaka University have described piperazine derivatives acting as drug efflux pump inhibitors reported to be useful for the treatment of bacterial infections.

Researchers have used a combination of genetic manipulation and protein structural analysis to determine how the position of 'bulky' amino acids influences the ability of efflux pump inhibitors to ...

image: The inhibitor-binding site of the wild-type MexB pump. (a) The crystal structure of the inhibitor ABI-PP bound to the MexB trimer. Three MexB monomers are shown in green, blue, and red, ...